Skip to content
James A. Geraghty, a board director of five NASDAQ-listed biotech companies and author, joins a conversation with Paul Hastings, CEO of Nkarta Therapeutics and […]
‘Inside the Orphan Drug Revolution’ author speaks today – read an excerpt of the book Read More »
Legislation to reauthorize Food and Drug Administration (FDA) user fee agreements passed the House with bipartisan support Wednesday, and the Senate is expected to
House votes to reauthorize FDA user fees; Senate’s up next Read More »
A May 16 letter signed by 125 patient advocacy groups urges congressional leaders to restore the access to COVID treatment for the uninsured that
Patient groups urge lawmakers to restore access to COVID treatment Read More »
Novavax’s two-dose vaccine against COVID-19 moved closer to Emergency Use Authorization (EUA) from the Food and Drug Administration yesterday when the FDA’s Vaccines and
FDA advisory committee recommends EUA for Novavax COVID vaccine Read More »
Moderna announced yesterday that doses have been given to participants in a Phase 3 clinical trial of seasonal influenza vaccines using the revolutionary mRNA
Moderna launches Phase 3 trial of mRNA flu vaccine candidate Read More »
Projected Medicare Part D costs in 2022 are slightly lower than in 2021 and slower growth in overall drug prices is one of the
Medicare trustees say they expect Part D costs to fall in 2022 Read More »
Since health officials confirmed the first recent case of monkeypox in a human on May 7, the virus has now spread to more than
Yes, we have a monkeypox vaccine – thanks to investment in medical preparedness Read More »
Biopharmaceutical company Global Blood Therapeutics, Inc., a member of the Biotechnology Innovation Organization (BIO), announced Monday that two of its treatments undergoing clinical trials
GBT’s inclacumab and GBT601 for sickle cell disease receive favorable FDA designations Read More »
The number of COVID-19 cases has been rising in the United States, according to the Centers for Disease Control and Prevention (CDC). We are
Omicron subvariants BA.4 and BA.5 cause increasing number of COVID-19 cases Read More »
After many delays, the Food and Drug Administration’s Advisory Committee on vaccines and related biological products will discuss on June 7 the request for
FDA to review Novavax’s COVID vaccine EUA application Read More »
